论文部分内容阅读
目的比较诺和锐30和优泌乐50治疗口服药不达标的2型糖尿病患者临床疗效和安全性。方法 26例2型糖尿病患者进行皮下注射诺和锐30,2次/d,90 d后进行糖化血红蛋白测定,然后对上述糖尿病患者行优泌乐50替换治疗,90 d后测定糖化血红蛋白。比较两种胰岛素治疗方案的糖化血红蛋白下降幅度及低血糖发生率。结果两种治疗方案在餐后2 h血糖、糖化血红蛋白方面差异有统计学意义(P<0.05),优泌乐50组处于优势。在低血糖发生率及空腹血糖和胰岛素用量方面,两者差异无统计学意义(P>0.05)。结论优泌乐50在餐后血糖控制及减少低血糖方面明显优于诺和锐30。
Objective To compare the clinical efficacy and safety of Novo-Rui-30 and You-Guang-Ru-50 in the treatment of type 2 diabetes who do not meet the oral requirements. Methods Twenty-six patients with type 2 diabetes underwent subcutaneous injection of Novolin at 30, 2, and 90 days. HbA1c levels were measured after 90 days. Patients with diabetes mellitus underwent exobaric acid 50 replacement therapy. HbA1c levels were measured 90 days later. Glycemic hemoglobin decline and hypoglycemia incidence were compared between the two insulin regimens. Results There was significant difference in blood glucose and HbA1c between the two treatment regimens at 2 h postprandial (P <0.05). In the incidence of hypoglycemia and fasting blood glucose and insulin dosage, the difference was not statistically significant (P> 0.05). Conclusion Uehara 50 is significantly superior to Novo-Rui 30 in controlling postprandial blood glucose and reducing hypoglycemia.